BeOne Medicines annual gross profit
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Gross Profit Growth & History (ONC)
BeOne Medicines's gross profit was $4.67B for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.67B | $1.46B | +45.34% |
| 2024 | 2024-12-31 | $3.22B | $1.14B | +54.71% |
| 2023 | 2023-12-31 | $2.08B | $949.4M | +84.06% |
| 2022 | 2022-12-31 | $1.13B | $118.1M | +11.67% |
| 2021 | 2021-12-31 | $1.01B | $773.2M | +324.56% |
| 2020 | 2020-12-31 | $238.2M | −$118.8M | −33.28% |
| 2019 | 2019-12-31 | $357.0M | $187.5M | +110.61% |
| 2018 | 2018-12-31 | $169.5M | −$63.9M | −27.38% |
| 2017 | 2017-12-31 | $233.4M | $232.3M | +21714.30% |
| 2016 | 2016-12-31 | $1.1M | — | — |
BeOne Medicines quarterly gross profit
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.53B | $379.8M | +33.01% |
| Q1 2026 | 2026-03-31 | $1.35B | $393.9M | +41.37% |
| Q4 2025 | 2025-12-31 | $1.36B | $388.5M | +40.16% |
| Q3 2025 | 2025-09-30 | $1.22B | $384.6M | +46.28% |
| Q2 2025 | 2025-06-30 | $1.15B | $359.7M | +45.47% |
| Q1 2025 | 2025-03-31 | $952.3M | $325.6M | +51.95% |
| Q4 2024 | 2024-12-31 | $967.3M | $438.7M | +82.99% |
| Q3 2024 | 2024-09-30 | $831.1M | $146.1M | +21.33% |
| Q2 2024 | 2024-06-30 | $791.0M | $291.8M | +58.44% |
| Q1 2024 | 2024-03-31 | $626.7M | $260.7M | +71.23% |
| Q4 2023 | 2023-12-31 | $528.6M | $222.0M | +72.41% |
| Q3 2023 | 2023-09-30 | $685.0M | $373.9M | +120.20% |
| Q2 2023 | 2023-06-30 | $499.3M | $228.9M | +84.64% |
| Q1 2023 | 2023-03-31 | $366.0M | $124.6M | +51.63% |
| Q4 2022 | 2022-12-31 | $306.6M | $141.1M | +85.31% |
| Q3 2022 | 2022-09-30 | $311.1M | $152.1M | +95.62% |
| Q2 2022 | 2022-06-30 | $270.4M | $156.7M | +137.76% |
| Q1 2022 | 2022-03-31 | $241.4M | −$331.8M | −57.89% |
| Q4 2021 | 2021-12-31 | $165.4M | $86.4M | +109.35% |
| Q3 2021 | 2021-09-30 | $159.0M | $89.1M | +127.32% |
| Q2 2021 | 2021-06-30 | $113.7M | $62.4M | +121.57% |
| Q1 2021 | 2021-03-31 | $573.2M | $535.3M | +1411.97% |
| Q4 2020 | 2020-12-31 | $79.0M | $40.1M | +103.10% |
| Q3 2020 | 2020-09-30 | $70.0M | $39.9M | +132.92% |
| Q2 2020 | 2020-06-30 | $51.3M | −$174.2M | −77.24% |
| Q1 2020 | 2020-03-31 | $37.9M | −$24.7M | −39.41% |
| Q4 2019 | 2019-12-31 | $38.9M | −$10.6M | −21.36% |
| Q3 2019 | 2019-09-30 | $30.0M | −$15.5M | −33.98% |
| Q2 2019 | 2019-06-30 | $225.5M | $179.0M | +384.46% |
| Q1 2019 | 2019-03-31 | $62.6M | $34.6M | +123.52% |
| Q4 2018 | 2018-12-31 | $49.5M | — | — |
| Q3 2018 | 2018-09-30 | $45.5M | −$172.8M | −79.16% |
| Q2 2018 | 2018-06-30 | $46.5M | — | — |
| Q1 2018 | 2018-03-31 | $28.0M | — | — |
| Q3 2017 | 2017-09-30 | $218.3M | — | — |
BeOne Medicines gross profit trends
Over the last five fiscal years, BeOne Medicines's gross profit increased from $238.2M to $4.67B, a change of $4.44B. The latest reported quarter, Q2 2026, shows $1.53B.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗Community posts
BeOne’s initial clinical results support planned late-stage studies
BeOne Medicines ($ONC) disclosed new dose-optimization findings for BGB-B2033 in heavily pretreated liver cancer. At the proposed Phase 3 dose, the bispecific antibody produced confirmed responses in 36% of patients, with an estimated 74.1% ...
